Back to results
US 11,236,170 B2Granted
Bispecific checkpoint inhibitor antibodies
AssigneeXencor, Inc.
InventorsMatthew Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon, Alex Nisthal
Life of this patent
Estimating the term…
Abstract
The present invention is directed to heterodimeric anti-PD-1 x anti-CTLA-4. Also provided are nucleic acid compositions that encode the antibodies, expression vector compositions that include the nucleic acids, and host cells that include the expression vector compositions.
Claims5
A heterodimeric anti-PD1 x anti-CTLA-4 antibody comprising:
- a) a first monomer comprising a VH-CH1-hinge-CH2-CH3 monomer having the amino acid sequence of SEQ ID NO:
- 38518;
- b) a second monomer comprising an anti-PD-1 scFv-linker-CH2-CH3 monomer having the amino acid sequence of SEQ ID NO:
- 38523;
- and
- c) a third monomer comprising a VL-CL monomer having the amino acid sequence of SEQ ID NO:
- 38533, wherein VH is a variable heavy domain, VL is a variable light domain, and VH and VL form a CTLA4 binding domain.
4 more elements
Dependencies are inferred from the claim text.